

United States Patent and Trademark Office Expedites COVID-Related Trademark Applications

by Andrew L. Goldstein

A FREEBORN & PETERS LLP CLIENT ALERT

The United States Patent and Trademark Office (“USPTO”) generally processes trademark applications in the order in which they are received, often taking up to three months for the initial examination of a trademark application. However, the USPTO announced that it will expedite the examination of trademark applications that cover medical products and services related to COVID-19 and that it will waive the fee to do so.



The USPTO stated that in response to the COVID-19 outbreak, the development of medical products and services to combat the COVID-19 virus, along with moving successful products to market as soon as possible, is critical. Therefore, the USPTO is accepting petitions to advance the initial examination of applications for marks used to identify qualifying COVID-19 medical products and services, and it is waiving the usual fee for such petitions. Applications seeking to be expedited can also include goods or services related to such COVID-19 medical products and services.

The following are what the USPTO considers to be qualifying COVID-19 medical-related goods and services:

- pharmaceutical products or medical devices such as diagnostic tests, ventilators, and personal protective equipment, including surgical masks, face shields, gowns, and gloves, that prevent, diagnose, treat, or cure COVID-19 and are subject to approval by the United States Food and Drug Administration; and
- medical services or medical research services for the prevention, diagnosis, treatment of, or cure for COVID-19.

The approvals referenced above for pharmaceutical products or medical devices may include, but are not limited to, an Investigational New Drug (IND) application, an Investigational Device Exemption (IDE), a New Drug Application (NDA), a Biologics License Application (BLA), a Premarket Approval (PMA), or an Emergency Use Authorization (EUA). Information on INDs, IDEs, NDAs, BLAs, PMAs, and EUAs is available at www.fda.gov.

The petition must include a statement of facts setting forth the applicant’s COVID-19 medical goods or services and an explanation of why the goods or services are of a type that qualify for prioritized examination, including the section of the US Code of Federal Regulations (CFR) under which the goods are regulated.

The USPTO said that the goal of the prioritized examination is to expedite the initial examination process for qualifying applications. If a petition is granted, the application will immediately be assigned to a USPTO examining attorney for review, which the USPTO estimates will expedite examination process by approximately two months.

On June 30, the USPTO launched a webpage [here](#) providing resources and information about the program.

If you are interested in filing a trademark application for COVID-19 medical-related goods and services, or if you require assistance in doing so, please contact Andrew Goldstein or another member of Freeborn & Peters LLP's Intellectual Property Practice Group. Stay tuned for further developments on [Freeborn's COVID-19 webpage](#).

ABOUT THE AUTHOR



Andrew L. Goldstein

Senior Counsel

Chicago Office
(312) 360-6438

agoldstein@freeborn.com

Andrew focuses his practice in the area of Intellectual Property and Information Technology. He has extensive experience in the areas of intellectual property law, including trademark, copyright, trade dress; internet, website, cloud computing, technology, outsourcing, IoT and computer law in general; advertising, marketing, and promotion law; and entertainment law, including video production, theater and dance-related matters.

140+ Attorneys. 5 Offices.

Freeborn & Peters LLP is a full-service law firm with international capabilities and offices in Chicago, Ill.; New York, Ny; Richmond, Va.; Springfield, Ill.; and Tampa, Fla. Freeborn is always looking ahead and seeking to find better ways to serve its clients. It takes a proactive approach to ensure its clients are more informed, prepared and able to achieve greater success – not just now, but also in the future. While the firm serves clients across a very broad range of sectors, it has also pioneered an interdisciplinary approach that serves the specific needs of targeted industries.

Freeborn's major achievements in litigation are reflective of the firm's significant growth over the last several years and its established reputation as a Litigation Powerhouse®. Freeborn has one of the largest litigation departments among full-service firms of its size – currently with more than 90 litigators, which represents about two-thirds of the firm's lawyers.

Freeborn is a firm that genuinely lives up to its core values of integrity, effectiveness, teamwork, caring and commitment, and embodies them through high standards of client service and responsive action. Its lawyers build close and lasting relationships with clients and are driven to help them achieve their legal and business objectives.

For more information visit: www.freeborn.com

CHICAGO

311 South Wacker Drive
Suite 3000
Chicago, IL 60606
(312) 360-6000
(312) 360-6520 fax

NEW YORK

230 Park Avenue
Suite 630
New York, NY 10169
(212) 218-8760
(212) 218-8761 fax

SPRINGFIELD

217 East Monroe Street
Suite 202
Springfield, IL 62701
(217) 535-1060
(217) 535-1069 fax

RICHMOND

901 East Byrd Street
Suite 950
Richmond, VA 23219
(804) 644-1300
(804) 644-1354 fax

TAMPA

1 Tampa City Center
201 North Franklin Street
Suite 3550
Tampa, FL 33602
(813) 488-2920

Disclaimer: This publication is made available for educational purposes only, as well as to provide general information about the law, not specific legal advice. It does not establish an attorney/client relationship between you and Freeborn & Peters LLP, and should not be used as a substitute for competent legal advice from a licensed professional in your state.

© 2020 Freeborn & Peters LLP. All rights reserved. Permission is granted to copy and forward all articles and text as long as proper attribution to Freeborn & Peters LLP is provided and this copyright statement is reproduced.